Roche’s Tecentriq gets CHMP recommendation as adjuvant treatment for early NSCLC

Tecentriq is indicated as an adjuvant treatment for NSCLC in adults with a high risk of recurrence. Credit: F. Hoffmann-La Roche Ltd.